Search research articles
Contact Us
Filters
Showing results (101-110 of 176) with videos related to
Page
of 18
Sort By:
The New England Journal of Medicine
|
December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Michael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Cancers
|
February 15, 2022
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, et al.
Eclinicalmedicine
|
April 1, 2025
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Clémentine Sarkozy, Thierry Jo Molina, Sydney Dubois, et al.
Leukemia
|
April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood
|
April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia
Eric Durot, Damien Roos-Weil, Adrien Chauchet, et al.
British Journal of Haematology
|
April 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, et al.
Haematologica
|
December 1, 2022
ALK-negative anaplastic large cell lymphoma with <i>DUSP22</i> rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
David Sibon, Bettina Bisig, Christophe Bonnet, et al.
Blood
|
November 14, 2022
BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1
Lorric Delage, Mireille Lambert, Émilie Bardel, et al.
Blood Advances
|
January 5, 2024
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
Samuel Vic, Jean-Baptiste Thibert, Emmanuel Bachy, et al.
Blood Advances
|
August 24, 2021
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 176) with videos related to
Sort By:
Page
of 18
The New England Journal of Medicine
|
December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Michael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Cancers
|
February 15, 2022
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, et al.
Eclinicalmedicine
|
April 1, 2025
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Clémentine Sarkozy, Thierry Jo Molina, Sydney Dubois, et al.
Leukemia
|
April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood
|
April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia
Eric Durot, Damien Roos-Weil, Adrien Chauchet, et al.
British Journal of Haematology
|
April 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, et al.
Haematologica
|
December 1, 2022
ALK-negative anaplastic large cell lymphoma with <i>DUSP22</i> rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
David Sibon, Bettina Bisig, Christophe Bonnet, et al.
Blood
|
November 14, 2022
BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1
Lorric Delage, Mireille Lambert, Émilie Bardel, et al.
Blood Advances
|
January 5, 2024
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
Samuel Vic, Jean-Baptiste Thibert, Emmanuel Bachy, et al.
Blood Advances
|
August 24, 2021
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, et al.
Page
of 18